TY  - JOUR 
AU  - Lozano, Maria L
AU  - Mingot-Castellano, Maria E
AU  - Perera, Maria M
AU  - Jarque, Isidro
AU  - Campos-Alvarez, Rosa M
AU  - Gonzalez-Lopez, Tomas J
AU  - Carreno-Tarragona, Gonzalo
AU  - Bermejo, Nuria
AU  - López Fernández, María Fernanda
AU  - de Andres, Aurora
AU  - Valcarcel, David
AU  - Casado-Montero, Luis F
AU  - Alvarez-Roman, Maria T
AU  - Orts, Maria I
AU  - Novelli, Silvana
AU  - Revilla, Nuria
AU  - Gonzalez-Porras, Jose R
AU  - Bolanos, Estefania
AU  - Rodríguez López, Manuel
AU  - Orna-Montero, Elisa
AU  - Vicente, Vicente
PY  - 2019
SN  - 2045-2322
UR  - http://hdl.handle.net/20.500.11940/15891
AB  - Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clinical practice for the treatment of patients with immune thrombocytopenia (ITP), about novel risk factors for vascular events (VE) with these drugs, nor...
LA  - eng
KW  - Purpura
KW  - Adult
KW  - Middle Aged
KW  - Thrombopoietin
KW  - Benzoates
KW  - Follow-Up Studies
KW  - Survival Rate
KW  - Hydrazines
KW  - Humans
KW  - Pyrazoles
KW  - Recombinant Fusion Proteins
KW  - Young Adult
KW  - Aged
KW  - Retrospective Studies
KW  - Prognosis
TI  - Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
DO  - 10.1038/s41598-019-53209-y
T2  - Scientific Reports
KW  - CHUAC
KW  - CHUVI
VL  - 9
ER  -